NCT06784739 COMMUNITY - the COVID-19 Immunity Study
| NCT ID | NCT06784739 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Danderyd Hospital |
| Condition | COVID 19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,500 participants |
| Start Date | 2020-04-15 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,500 participants in total. It began in 2020-04-15 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients. The study aims to enroll a total of 5,000 healthcare workers and 500 COVID-19 patients. All participants are enrolled at Danderyd Hospital in Stockholm, Sweden. Participants will be followed every four months with blood and mucosal sampling in addition to demographic and clinical data provided by the participants and from national registries. Primary outcome: \- Antibody responses in blood and mucosa following SARS-CoV-2 infection and/or vaccination Secondary outcomes: * Cellular immune responses following SARS-CoV-2 infection and/or vaccination * Antibody responses in blood and mucosa following following Influenza A/B infection and/or vaccination * Antibody responses in blood and mucosa following following RSV A/B infection Blood and mucosal samples are collected every 4 months and at tighter intervals in sub studies. PCR testing is conducted upon symptoms of respiratory infections and with regular intervals regardless of symptomatology in sub studies. Participants provide detailed demographic and clinical data through a smart phone application-based questionnaire. Data on infection and vaccination history is collected from national registries
Eligibility Criteria
Inclusion Criteria: * Health care workers: Employment at Danderyd hospital at time of enrollment * COVID-19 patients: Admitted to Danderyd Hospital with confirmed SARS-CoV-2 infection at time of enrollment Exclusion Criteria: * No exclusion criteria
Contact & Investigator
Charlotte Thålin, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
Frequently Asked Questions
Who can join the NCT06784739 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID 19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06784739 currently recruiting?
Yes, NCT06784739 is actively recruiting participants. Contact the research team at nina.greilert@ki.se for enrollment information.
Where is the NCT06784739 trial being conducted?
This trial is being conducted at Stockholm, Sweden, Stockholm, Sweden.
Who is sponsoring the NCT06784739 clinical trial?
NCT06784739 is sponsored by Danderyd Hospital. The principal investigator is Charlotte Thålin, MD, PhD at Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital. The trial plans to enroll 5,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.